ORPHA.CO
Price:
$1120
Market Cap:
$46.72M
Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.[Read more]
Industry
Biotechnology
IPO Date
2017-11-21
Stock Exchange
CPH
Ticker
ORPHA.CO
According to Orphazyme A/S’s latest financial reports and current stock price. The company's current PE Ratio is -0.06. This represents a change of -100.00% compared to the average of 4.22K of the last 4 quarters.
The mean historical PE Ratio of Orphazyme A/S over the last ten years is -5227.65. The current -0.06 PE Ratio has changed -99.89% with respect to the historical average. Over the past ten years (40 quarters), ORPHA.CO's PE Ratio was at its highest in in the March 2024 quarter at 10.48K. The PE Ratio was at its lowest in in the March 2021 quarter at -17617.54.
Average
-5227.65
Median
-3430.97
Minimum
-17183.93
Maximum
0
Discovering the peaks and valleys of Orphazyme A/S PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = 0%
Minimum Annual PE Ratio = -17183.93
Year | PE Ratio | Change |
---|---|---|
2023 | -1787.09 | 536.80% |
2022 | -280.64 | -70.66% |
2021 | -956.52 | -68.18% |
2020 | -3005.72 | -29.95% |
2019 | -4290.84 | 11.27% |
2018 | -3856.23 | -47.43% |
2017 | -7335.49 | -45.98% |
2016 | -13580.05 | -20.97% |
2015 | -17183.93 | -Infinity% |
2015 | 0 | 0% |
The current PE Ratio of Orphazyme A/S (ORPHA.CO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1008.08
5-year avg
-2064.16
10-year avg
-5227.65
Orphazyme A/S’s PE Ratio is greater than Zealand Pharma A/S (-72.81), less than Ambu A/S (69.80), greater than BioPorto A/S (-13.88), less than Bavarian Nordic A/S (22.85), less than Genmab A/S (17.78),
Company | PE Ratio | Market cap |
---|---|---|
-72.81 | $58.67B | |
69.80 | $33.92B | |
-13.88 | $806.48M | |
22.85 | $16.27B | |
17.78 | $96.40B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Orphazyme A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Orphazyme A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Orphazyme A/S's PE Ratio?
How is the PE Ratio calculated for Orphazyme A/S (ORPHA.CO)?
What is the highest PE Ratio for Orphazyme A/S (ORPHA.CO)?
What is the 3-year average PE Ratio for Orphazyme A/S (ORPHA.CO)?
What is the 5-year average PE Ratio for Orphazyme A/S (ORPHA.CO)?
How does the current PE Ratio for Orphazyme A/S (ORPHA.CO) compare to its historical average?